Predicting trajectories of recovery in prostate cancer patients undergone Robot-Assisted Radical Prostatectomy (RARP).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
01
2019
accepted:
18
03
2019
entrez:
5
4
2019
pubmed:
5
4
2019
medline:
21
1
2020
Statut:
epublish
Résumé
To identify trends of patients' urinary and sexual dysfunctions from a clinical and psychological perspective and understand whether sociodemographic and medical predictors could differentiate among patients following different one-year longitudinal trajectories. An Italian sample of 478 prostate cancer patients undergone Robot-Assisted Radical Prostatectomy completed the EPIC-26 survey between July 2015 and July 2016 at the pre-hospitalization (T0), 45 days (T1) and 3 (T2), 6 (T3), 9 (T4), and 12 months (T5) after surgery. Sociodemographic and clinical characteristics (age, BMI, diabetes, nerve-sparing procedure) were also collected. Latent Class Growth Analysis was conducted separately for sexual dysfunction and urinary incontinence EPIC-26 subscales. The association between membership in the two longitudinal trajectories of urinary and sexual dysfunctions was assessed by considering Chi-square test and its related contingency table. People who have a high level of urinary incontinence at T1 are likely to have a worse recovery. Age, BMI and pre-surgical continence may affect the level of incontinence at T1 and the recovery trajectories. Patients with low and moderate sexual problems at T1 can face a moderate linear recovery, while people with high level of impotence immediately after surgery may take a longer period to solve sexual dysfunctions. Age and the pre-surgical sexual condition may impact the recovery. Finally, a great proportion of patients reported both steady problems in sexual function and constant high levels of urinary incontinence over time. This study highlights different categories of patients at risk who may be important to know in order to develop personalized medical pathways and predictive models in a value-based healthcare.
Identifiants
pubmed: 30946773
doi: 10.1371/journal.pone.0214682
pii: PONE-D-19-00739
pmc: PMC6448842
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0214682Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Multidiscip Healthc. 2017 Mar 21;10:101-106
pubmed: 28356752
West J Nurs Res. 2016 Apr;38(4):508-20
pubmed: 26333302
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 27726215
Can J Urol. 2016 Oct;23(5):8451-8456
pubmed: 27705730
Int J Cancer. 2018 Feb 15;142(4):741-746
pubmed: 29023685
PLoS One. 2017 Aug 29;12(8):e0183905
pubmed: 28850579
Prostate Cancer Prostatic Dis. 2012 Jun;15(2):120-7
pubmed: 22212706
Transl Androl Urol. 2015 Aug;4(4):413-20
pubmed: 26816840
Urology. 2010 Nov;76(5):1245-50
pubmed: 20350762
Circulation. 2000 Aug 8;102(6):630-5
pubmed: 10931802
J Urol. 2011 Jul;186(1):204-8
pubmed: 21575975
Ecancermedicalscience. 2014 Feb 11;8:400
pubmed: 24567757
Pain. 2016 Jan;157(1):225-234
pubmed: 26397929
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
BJU Int. 2016 Oct;118(4):641-5
pubmed: 26906935
Psychol Med. 2012 Jul;42(7):1383-96
pubmed: 22053816
Health Psychol. 2011 Nov;30(6):683-92
pubmed: 21728421
BMC Urol. 2015 Apr 10;15:28
pubmed: 25885890
J Endourol. 2014 Feb;28(2):172-7
pubmed: 23987521
CA Cancer J Clin. 2014 Jul-Aug;64(4):225-49
pubmed: 24916760
Radiother Oncol. 2016 Jan;118(1):85-91
pubmed: 26780999
Eur J Intern Med. 2014 Oct;25(8):685-8
pubmed: 25060407
J Sex Med. 2008 Mar;5(3):693-704
pubmed: 18194174
PLoS One. 2016 Sep 02;11(9):e0161840
pubmed: 27589065
J Adolesc. 2006 Dec;29(6):981-1004
pubmed: 17045640
J Eval Clin Pract. 2011 Aug;17(4):594-6
pubmed: 21679280
N Engl J Med. 2013 Jan 31;368(5):436-45
pubmed: 23363497
Appl Psychol Health Well Being. 2018 Nov;10(3):434-456
pubmed: 30230683
Am J Community Psychol. 2005 Sep;36(1-2):49-70
pubmed: 16134044
Ecancermedicalscience. 2016 Jul 26;10:659
pubmed: 27563354
Curr Urol. 2017 Nov;11(1):16-20
pubmed: 29463972
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Health Qual Life Outcomes. 2019 Aug 29;17(1):147
pubmed: 31464649
Ann Surg. 2008 Oct;248(4):503-9
pubmed: 18936561
Cancer Nurs. 2007 Nov-Dec;30(6):E19-32
pubmed: 18025909
J Urol. 2010 Mar;183(3):1087-91
pubmed: 20092834
J Int Med Res. 2018 Jan;46(1):421-429
pubmed: 28718690
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Neurourol Urodyn. 2018 Sep;37(7):2263-2270
pubmed: 29566265
Clin Interv Aging. 2010 Aug 09;5:187-97
pubmed: 20711438
J Clin Exp Neuropsychol. 1992 Jul;14(4):575-92
pubmed: 1400920
Lancet. 1996 Feb 17;347(8999):417-21
pubmed: 8618481
Int J Behav Med. 2018 Aug;25(4):399-409
pubmed: 29856009
Qual Life Res. 2019 Feb;28(2):481-490
pubmed: 30276505
Psychooncology. 2017 Oct;26(10):1576-1585
pubmed: 27943512
Urol Oncol. 2015 Feb;33(2):69.e19-28
pubmed: 24433753
J Cancer Educ. 2017 Jun;32(2):228-237
pubmed: 26854084
J Alzheimers Dis. 2010;22(4):1169-80
pubmed: 20930287
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Urol Oncol. 2017 Feb;35(2):40-41
pubmed: 27998677